Correction on Vertex Hepatitis C Drug Story
26 July 2013 - 9:22AM
Dow Jones News
"Vertex: FDA Puts Partial Hold on Study of Hepatitis C Drug," at
6:07 p.m. ET, mistakenly implied in the fourth paragraph that no
serious adverse events or safety issues were reported in studies of
the drug at any dose. It should have specified that in patients who
were given 100-milligram or 200-milligram doses of the drug in the
European study, no serious adverse events or liver or cardiac
safety issues were reported.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024